Our Company

About Alnylam

ALNYLAM IS LEADING THE RNAi REVOLUTION™

Alnylam is a leading biopharmaceutical company and the pioneer in RNA interference (RNAi) – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them.

Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of RNAi medicine possible.

In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. Our approved RNAi therapeutics are currently available in more than 60 countries.

What’s in a Name?

AL-NY-LAM. Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Alnylam is derived from “Alnilam,” the bright centre star in the constellation Orion’s belt, which has been used by navigators for thousands of years and symbolises our passion for discovery.

The Leader in RNAi

Medicines based on RNAi work by “silencing” or disabling the production (“expression”) of the genes that cause specific diseases. Since our medicines work at a genetic level, we believe that we can develop small interfering RNAs (siRNAs) that can silence virtually any gene in the genome, meaning that the diseases we’re treating with RNAi today are just the beginning of what’s possible.

COMMITMENT TO PEOPLE

Our work extends far beyond the therapies we develop. Corporate responsibility is integrated throughout our business, from the way we listen to patients and design clinical trials, to how we empower our employees, advance ethical standards, and reduce our environmental impact.

We accept bold challenges to improve the health of humanity and believe that our actions as a company can be a force for good in the world.

Learn more about Alnylam’s corporate responsibility in the UK here.

GRANTS AND GIVING

The Alnylam Grants and Giving Office is committed to supporting innovative, high-quality initiatives that provide healthcare professionals and patients with evidence-based, clinically-relevant and performance-based education, and improve patient health. Activities and programmes should strive to ultimately improve patient care and must be compliant with all applicable legal and regulatory requirements.

Find out about the areas of interest, process and funding types that will be considered here.